PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Ciclosporin - Transplant immunosuppression

PAD Profile : Ciclosporin - Transplant immunosuppression

Brand Names Include :
Neoral, Sandimmun

Traffic Light Status

Status 1 of 2.

Status :
Red
Important
Formulations :
  • Capsules
  • Oral solution
Important Information :
For NEW patients: RED drug for post-transplant. Funded by NHS England. GPs should not accept any new requests to prescribe post-transplant.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Blue
Important
Formulations :
  • Not Specified
Important Information :
For EXISTING patients only: GPs may continue to prescribe for existing post-transplant patients only. MHS England are looking to repatriate the patients in the future. GPs must not accept requests to prescribe for new patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
01 April 2013
Not Set
FOR EXISTING PATIENTS: GPs should continue to prescribe these treatments. NHS England are looking to repatriate these patients in the future. The Medicines Management Team will be in contact with prescribers when they have more information FOR NEW PATIENTS ONLY: The prescribing of Ciclosporin is considered a RED drug post transplant only and is now funded via NHS England for this indication.

Associated BNF Codes

08. Malignant Disease and Immunosuppression
08.02.02. Corticosteroids and other immunosuppressants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More